Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

629 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients.
Perea G, Domingo A, Villamor N, Palacios C, Juncà J, Torres P, Llorente A, Fernández C, Tormo M, Queipo de Llano MP, Bargay J, Gallart M, Florensa L, Vivancos P, Martí JM, Font L, Berlanga J, Esteve J, Bueno J, Ribera JM, Brunet S, Sierra J, Nomdedéu JF; CETLAM GroupSpain. Perea G, et al. Among authors: ribera jm. Leuk Res. 2005 Oct;29(10):1109-16. doi: 10.1016/j.leukres.2005.02.015. Leuk Res. 2005. PMID: 16095690
Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
Muñoz L, Nomdedéu JF, Villamor N, Guardia R, Colomer D, Ribera JM, Torres JP, Berlanga JJ, Fernández C, Llorente A, Queipo de Llano MP, Sánchez JM, Brunet S, Sierra J; Spanish CETLAM Group. Muñoz L, et al. Among authors: ribera jm. Leukemia. 2003 Jan;17(1):76-82. doi: 10.1038/sj.leu.2402708. Leukemia. 2003. PMID: 12529663
CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Pérez-García A, Brunet S, Berlanga JJ, Tormo M, Nomdedeu J, Guardia R, Ribera JM, Heras I, Llorente A, Hoyos M, Esteve J, Besalduch J, Bueno J, Sierra J, Gallardo D; Grupo cooperativo para el estudio y tratamiento de las leucemias agudas. Pérez-García A, et al. Among authors: ribera jm. Leukemia. 2009 Mar;23(3):486-91. doi: 10.1038/leu.2008.339. Epub 2008 Dec 18. Leukemia. 2009. PMID: 19092854 Clinical Trial.
Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size.
Nomdedeu J, Bussaglia E, Villamor N, Martinez C, Esteve J, Tormo M, Estivill C, Queipo MP, Guardia R, Carricondo M, Hoyos M, Llorente A, Juncà J, Gallart M, Domingo A, Bargay J, Mascaró M, Moraleda JM, Florensa L, Ribera JM, Gallardo D, Brunet S, Aventin A, Sierra J; Spanish CETLAM. Nomdedeu J, et al. Among authors: ribera jm. Leuk Res. 2011 Feb;35(2):163-8. doi: 10.1016/j.leukres.2010.05.015. Epub 2010 Jun 9. Leuk Res. 2011. PMID: 20542566 Clinical Trial.
Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
Nomdedéu JF, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J, Tormo M, Duarte R, Salamero O, de Llano MP, García A, Bargay J, Heras I, Martí-Tutusaus JM, Llorente A, Ribera JM, Gallardo D, Aventin A, Brunet S, Sierra J; CETLAM Group. Nomdedéu JF, et al. Among authors: ribera jm. Leukemia. 2013 Nov;27(11):2157-64. doi: 10.1038/leu.2013.111. Epub 2013 Apr 15. Leukemia. 2013. PMID: 23584566
MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.
Díaz-Beyá M, Brunet S, Nomdedéu J, Tejero R, Díaz T, Pratcorona M, Tormo M, Ribera JM, Escoda L, Duarte R, Gallardo D, Heras I, Queipo de Llano MP, Bargay J, Monzo M, Sierra J, Navarro A, Esteve J; Cooperative AML group CETLAM (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias). Díaz-Beyá M, et al. Among authors: ribera jm. Leukemia. 2014 Apr;28(4):804-12. doi: 10.1038/leu.2013.281. Epub 2013 Sep 27. Leukemia. 2014. PMID: 24072101
Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation.
Sierra J, Brunet S, Grañena A, Olivé T, Bueno J, Ribera JM, Petit J, Besses C, Llorente A, Guardia R, Macía J, Rovira M, Badell I, Vela E, Díaz de Heredia C, Vivancos P, Carreras E, Feliu E, Montserrat E, Julía A, Cubells J, Rozman C, Domingo A, Ortega JJ. Sierra J, et al. Among authors: ribera jm. J Clin Oncol. 1996 Apr;14(4):1353-63. doi: 10.1200/JCO.1996.14.4.1353. J Clin Oncol. 1996. PMID: 8648394 Clinical Trial.
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J. Díaz-Beyá M, et al. Among authors: ribera jm. Blood Cancer J. 2015 Oct 2;5(10):e352. doi: 10.1038/bcj.2015.76. Blood Cancer J. 2015. PMID: 26430723 Free PMC article.
629 results